Ultrasonographic Response to Polarized Light Therapy in the Treatment of Atopic Dermatitis

Study Overview
=================
Brief Summary
-----------------
Non-atopic dermatitis (NAD) or eczema is a common inflammatory condition; potentially debilitating that can compromise quality of life. It is usually seen in childhood, but can onset within or persist into adulthood.

Detailed Description
-----------------
Polarized ultraviolet-free polychromatic light is used as therapeutic option for the treatment of wound healing and dermatological conditions. 40 male patients who had atopic dermatitis in the chronic stage, they were complaining from itching, inflammation and skin thickness in the arm, wrist, hand and leg will participate in this study.

Official Title
-----------------
Ultrasonographic Response to Polarized Light Therapy in the Treatment of Atopic Dermatitis

Conditions
-----------------
Chronic Atopic Dermatitis

Intervention / Treatment
-----------------
* Device: polarized light
* Drug: Topical corticosteroid ointment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patients' ages will ranged from 20 to 30 years. The subjects will be males. The duration of disease less than 1 year. Exclusion Criteria: patients who had skin malignancy in the area to be treated. The patients who had history of diabetes, circulatory or sensory disorders. Patients with acute infection in the area treated.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| polarized light group<br>group A (20 patients) will receive Polarized light therapy | Device: polarized light<br>* A Bioptron light therapy phototherapeutic device (Bioptron AG, Wollerau, Switzerland) with 5 cm treatment diameter (BIOPTRON MedAll®, 480-3400 nm, polarization level of 95%, power density 40 mW/cm2, energy density 2,4 J/cm2 per minute<br>|
| topical corticosteroid group<br>group B (20 patients) will receive topical corticosteroid therapy | Drug: Topical corticosteroid ointment<br>* corticosteroid 1 %.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ultrasonography | Ultrasound imaging system used to measure the thickness of the skin at the site of scale for both groups | 1-2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SCORAD Score | The SCORAD (Index) is the best validated scoring system in atopic dermatitis, To measure the extent of AD, the rule of nines is applied on a front/back drawing of the patient's inflammatory lesions. The extent can be graded from 0 to 100. The intensity part of the SCORAD consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness. Each item can be graded on a scale from 0 to 3. The subjective items include daily pruritus and sleeplessness. The SCORAD Index formula is: A/5 + 7B/2 + C. In this formula A is defined as the extent (0-100), B is defined as the intensity (0-18) and C is defined as the subjective symptoms (0-20). The maximal score of the SCORAD Index is 103. The objective SCORAD consist of the extent and the intensity items; the formula is A/5 + 7B/2. The maximal objective SCORAD score is 83 (with 10 additional points for severe disfiguring eczema of the face and hands). | 1-2 months |